CHUTES & LADDERS-BLUEBIRD PICKS UP HEFFRON AS EUROPEAN CHIEF
Bluebird Bio taps Heffron as Euro chief; Hildemann joins struggling Ipsen as CMO; Ivenix names Hansen as CEO.
JPM: BIOTECH, VC EXECS ON WHERE THE INDUSTRY SHOULD LOOK BEYOND CANCER
SAN FRANCISCO-Oncology is clearly a major medical and societal issue: a major killer that, while predominately affecting the older...
FRAZIER CLOSES $617M LIFE SCIENCE FUND, CREATING SCOPE FOR BIGGER BETS
Frazier Healthcare Partners has closed a $617 million life science fund, setting it up to place another set of bets spanning from company...
AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO
China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.
DURECT'S PAINKILLER GETS EVENLY SPLIT DECISION FROM EXPERT PANEL
A FDA advisory committee has issued an evenly split decision on Durect's extended-release formulation of bupivacaine. Durect's share...
ANALYSTS TIP BIOGEN TO FILE FOR ADUCANUMAB APPROVAL WITHIN WEEKS
Analysts at Jefferies expect Biogen to file for approval of aducanumab in Alzheimer's disease within weeks. Biogen, for its part, is...
AFTER IPO, BIONTECH NABS CELL THERAPY STARTUP NEON THERAPEUTICS
There's been a deal at the annual J.P. Morgan Healthcare Conference in San Francisco, but probably not with the largest names and certainly...
PFIZER TEAMS UP WITH INSILICO TO MINE DATA FOR DRUG TARGETS
Pfizer has entered into a research collaboration with Insilico Medicine. The partners will use Insilico's technology to identify real-world...
CANCER-KILLING VIRUS BOOSTS IMMUNO-ONCOLOGY RESPONSES IN MICE IN ASTELLAS-LED STUDY
A team of Japanese researchers led by Astellas Pharma's drug discovery unit engineered a piece of the vaccinia virus to carry two cytokines...
JPM TUESDAY ROUNDUP: PFIZER CEO TALKS UP PIPELINE, BOLT-ON DEALS THE NAME OF THE GAME IN 2020?
SAN FRANCISCO-The second day of the annual J.P. Morgan Healthcare Conference again saw no major M&A deals but did see some of the bigger...
NEKTAR PULLS NDA FOR PAIN DRUG AFTER UNANIMOUS ADCOMM REJECTION
Nektar Therapeutics has withdrawn the new drug application for its opioid oxycodegol after an advisory committee unanimously recommended...
EMENDO RAISES $61M TO BUILD ON TAKEDA-PARTNERED GENE EDITING PLATFORM
Emendo Biotherapeutics has raised a $61 million series B to take forward programs based on its gene editing platform. The New York-based...
GALAPAGOS BAGS OPTION ON 4 MORE FIBROCOR PROGRAMS
Galapagos has struck another deal to expand its fibrosis pipeline, picking up an option to license four Fibrocor programs. The deal...
JPM: MAYO CLINIC, NFERENCE LAUNCH AMBITIOUS DATA PLATFORM INITIATIVE
SAN FRANCISCO-Just a week after backing its $60 million series B round, the Mayo Clinic has tapped healthcare data analytics firm nference...
GUT LINK TO PARKINSON'S SPARKS TALK OF PROBIOTIC TREATMENT STRATEGY
A U.K.-based research team showed that in roundworm models of Parkinson's disease, probiotic Bacillus subtilis lessened the toxic buildup...
ACASTI BLAMES PHASE 3 LIPID-LOWERING FLOP ON PLACEBO RESPONSE
A phase 3 trial of Acasti Pharma's omega-3 drug CaPre has missed its primary endpoint, denting its hopes of challenging Amarin's Vascepa...
EX-MERCK SERONO CMO TAKES UP MEDICAL ROLE AT STRUGGLING IPSEN IN ITS EVOLVING C-SUITE
Steven Hildemann, M.D., Ph.D., is set to join Parisian biotech Ipsen as its new executive vice president and chief medical officer...
JPM MONDAY ROUNDUP: NO DEALS, BUT DRUG-PRICING STARTUP CAUSES THE BIGGEST NOISE
SAN FRANCISCO-Well, let's start with the obvious, a pattern that has been set for a good few years now: There were no M&A deals on...
ASTELLAS TEAMS WITH ADAPTIMMUNE TO CREATE CAR-T, TCR THERAPIES
Astellas has teamed up with Adaptimmune to develop allogeneic chimeric antigen receptor T-cell and T-cell receptor therapies. The agreement...
JPM: AS THE BIOTECH WORLD MAKES SAN FRANCISCO HOME FOR THE WEEK, JANSSEN HAS LONGER-TERM PLANS
As the annual J.P. Morgan Healthcare Conference kicks off in San Francisco this week, Janssen has unveiled plans to double down on...
World Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
World Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
2nd International Conference on Tissue Science and Regenerative Medicine
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
Interfacial molecular interactions of cellobiohydrolase Cel7A and its...
Molecular-scale mechanisms of the enzymatic breakdown of cellulosic biomass into fermentable sugars are still poorly understood, with a need for independent measurements of... Read more ...
Brassinosteroid overproduction improves lignocellulose quantity and quality...
As a leading biomass feedstock, poplar plants provide enormous lignocellulose resource convertible for biofuels and bio-chemicals. However, lignocellulose recalcitrance... Read more ...
US biofuel production and policy: implications for land use changes in...
It has been argued that the US biofuel policy is responsible for the land use changes in Malaysia and Indonesia. In this paper, following a short literature review that... Read more ...
Programmable nests for cells
Using DNA, smallest silica particles, and carbon nanotubes, researchers developed novel programmable materials. These nanocomposites can be tailored to various applications and... Read more ...
AveXis Inc.: Research Associate III
AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...
Mirati Therapeutics: Student Assistant
Mirati Therapeutics: Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations San... Read more ...
Inhibition of lignification of Zizania latifolia with radio frequency...
Zizania latifolia is easily lignified after harvesting, leading to the degradation of food quality and commercial value. Thus, this study evaluated the effect of radio... Read more ...
Performance difference of graph-based and alignment-based hybrid error...
The error-prone third-generation sequencing long reads can be corrected by the high-quality second-generation sequencing short reads, which is referred to as hybrid error... Read more ...
CHROMATIX: computing the functional landscape of many-body chromatin...
Chromatin interactions are important for gene regulation and cellular specialization. Emerging evidence suggests many-body spatial interactions play important roles in... Read more ...
Bachem: Validation Engineer II, QA
Bachem: Your Responsibilities The Validation Engineer II fulfills a critical role in GMP operations. This individual must plan and execute validation studies, Vista, CA, US ... Read more ...